Incyte (INCY) Misses Q1 EPS by 1c
Tweet
Share
E-mailGet Alerts INCY Hot Sheet
Price: $126.93 +1.83%
Revenue Growth %: +7.3%
Financial Fact:
Research and development: 143.18M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +7.3%
Financial Fact:
Research and development: 143.18M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Incyte (NASDAQ: INCY) reported Q1 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $159.28 million versus the consensus estimate of $155.21 million.
For earnings history and earnings-related data on Incyte (INCY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KB Home (KBH) Tops Q3 EPS by 16c
- Incyte (INCY) Reiterated at Neutral by Cantor Fitzgerald as Opzelura Attractive in HS
- Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
